Interpace Diagnostics Announces Cigna Coverage of ThyGenX®

Molecular Test Now Covered for Indeterminate Thyroid Nodules PARSIPPANY, N.J., July 27, 2017, IDXG, (GLOBE NEWSWIRE) Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that Cigna, one of the largest national health plans in the United States, has agreed to cover Interpace’s ThyGenX® test for Cigna’s 15 million members nationwide, with coverage effective immediately.  Cigna’s
http://bit.ly/2tMIh78